Substance abuse by schizophrenia patients is one of the most pressing problems facing the mental health system. The lifetime prevalence rate of substance abuse in schizophrenia is close to 50%, and estimates of current abuse range from 20-65%. Excessive substance use by schizophrenics increases the risk of symptom exacerbation and relapse, decreases compliance with treatment, serves as a significant source of conflict in families, and has a pernicious effect on neurological and cognitive functioning. Substance abusing schizophrenia patients are not adequately served by either traditional substance abuse programs or by purely psychiatric programs. There is an urgent need for empirically based programs that integrate essential elements of both psychiatric and substance abuse treatment. The purpose of this project is to conduct a Phase I project to develop and pilot test a multifaceted behavioral therapy to reduce substance use in schizophrenia patIents. The therapy will contain a number of elements, including: 1) social skills and problem solving training, 2) coping skills for managing stress and residual psychotic symptoms that contribute to substance use, 3) education about substance abuse coupled with goal setting; and 4) behavioral (social learning) techniques to decrease substance use and teach relapse prevention skills. Each component of the therapy program will be first be tested in preliminary clinical trials on groups of 6-8 dually diagnosed schizophrenia patients. The procedures will be modified as needed, and a carefully monitored pilot trial of the entire package will then be conducted on 32 patients. The final version will be manualized to allow replication in subsequent studies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA009406-04
Application #
2443488
Study Section
Special Emphasis Panel (SRCD (52))
Project Start
1994-09-30
Project End
2000-06-30
Budget Start
1997-07-01
Budget End
2000-06-30
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Psychiatry
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Bennett, Melanie E; Nidecker, Melissa; Strong Kinnaman, Joanna E et al. (2009) Examination of the inventory of drug use consequences with individuals with serious and persistent mental illness and co-occurring substance use disorders. Am J Drug Alcohol Abuse 35:385-90
Bennett, Melanie E; Bellack, Alan S; Brown, Clayton H et al. (2009) Substance dependence and remission in schizophrenia: A comparison of schizophrenia and affective disorders. Addict Behav 34:806-14
Carpenter, William T; Koenig, James I (2008) The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 33:2061-79
Kinnaman, Joanna E Strong; Bellack, Alan S; Brown, Clayton H et al. (2007) Assessment of motivation to change substance use in dually-diagnosed schizophrenia patients. Addict Behav 32:1798-813
Bellack, Alan S; Brown, Clayton H; Thomas-Lohrman, Shannon (2006) Psychometric characteristics of role-play assessments of social skill in schizophrenia. Behav Ther 37:339-52
Gearon, Jean S; Nidecker, Melissa; Bellack, Alan et al. (2003) Gender differences in drug use behavior in people with serious mental illnesses. Am J Addict 12:229-41
Gearon, J S; Bellack, A S; Rachbeisel, J et al. (2001) Drug-use behavior and correlates in people with schizophrenia. Addict Behav 26:51-61
Bellack, A S; Weinhardt, L S; Gold, J M et al. (2001) Generalization of training effects in schizophrenia. Schizophr Res 48:255-62
Bennett, M E; Bellack, A S; Gearon, J S (2001) Treating substance abuse in schizophrenia. An initial report. J Subst Abuse Treat 20:163-75
Gearon, J S; Bellack, A S (2000) Sex differences in illness presentation, course, and level of functioning in substance-abusing schizophrenia patients. Schizophr Res 43:65-70

Showing the most recent 10 out of 12 publications